Thomas Patrick Kelly - 15 Oct 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Financial Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
15 Oct 2025
Net transactions value
$0
Form type
4
Filing time
17 Oct 2025, 18:43:47 UTC
Previous filing
11 Jun 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kelly Thomas Patrick Chief Financial Officer 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 17 Oct 2025 0001410514

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +225,000 $0.000000 225,000 15 Oct 2025 Common Shares 225,000 $41.90 Direct F1
transaction XENE Restricted Share Units Award $0 +30,000 $0.000000 30,000 15 Oct 2025 Common Shares 30,000 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.